Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2004
The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancerIan Chau, Mark J Allen, David Cunningham, et al.
Clinical Colorectal Cancer|March 18, 2004
Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinomaTimothy J Price, Paul J Ross, Tamas Hickish, et al.
European Journal of Gastroenterology & Hepatology|September 14, 2016
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problemDimitrios C Ziogas, Dionysios Papadatos-Pastos, Kiruthikah Thillai, et al.
European Journal of Cancer (Oxford, England : 1990)|July 20, 2005
Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancerIan Chau, Andrew R Norman, David Cunningham, et al.
British Journal of Haematology|March 22, 2003
Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphomaIan Chau, Mark Harries, David Cunningham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2014
SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinomaAndrew X Zhu, Olivier Rosmorduc, T R Jeffry Evans, et al.
Plos One|May 2, 2018
Exome array analysis of adverse reactions to fluoropyrimidine-based therapy for gastrointestinal cancerMatthew Traylor, Jemma L Walker, Adele A Corrigan, et al.
Future Oncology (London, England)|May 7, 2020
NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121)Mairéad Geraldine McNamara, Lipika Goyal, Mark Doherty, et al.
The Lancet. Gastroenterology & Hepatology|June 27, 2017
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trialTim Meyer, Richard Fox, Yuk Ting Ma, et al.
British Journal of Cancer|June 22, 2018
Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trialAlison C Backen, Andre Lopes, Harpreet Wasan, et al.
Pageof 4